慢性硬膜下血肿介入治疗进展:从辅助治疗迈向一线治疗之路OA
Advances in endovascular therapy for chronic subdural hematoma:from adjunctive treatment toward first-line therapy
慢性硬膜下血肿(chronic subdural hematoma,CSDH)是神经外科常见疾病,随着人口老龄化进程加速及抗凝/抗血小板药物的广泛应用,其发病率持续攀升.传统钻孔引流术虽应用广泛,但术后复发率较高,且高龄患者手术耐受性差,亟须重新审视该疾病的临床处置策略.脑膜中动脉栓塞术(middle meningeal artery embolization,MMAE)通过阻断血肿包膜血供,从疾病进展的源头发挥治疗作用,尤其是近期发表的4项大型多中心随机对照研究(EMBOLISE、MAGIC-MT、STEM及EMPROTECT),从循证医学层面初步确立了MMAE的安全性与有效性.对于无急诊指征的症状性患者、抗凝/抗血小板药物使用者、复发性血肿及外科手术高风险患者,MMAE的临床获益尤为显著.同时,围术期针对供血动脉结构和血肿包膜灌注的多模影像学评估,有助于疗效预测和复发预警,可指导个体化的栓塞策略.在技术层面,复合手术、桡动脉入路栓塞等技术为特殊高风险患者提供了更安全的策略选择,不同栓塞材料在不同临床情境下亦有侧重.基于MMAE治疗的发展历程与现有证据,本文提出CSDH介入治疗理念的核心升级,即在包膜血供影像评估的指导下,从单一的脑膜中动脉栓塞转向血肿包膜血供的精准栓塞,进而达到精准有效的个体化治疗目标.
Chronic subdural hematoma(CSDH)is one of the most prevalent conditions in neurosurgical practice.Its incidence continues to rise in the context of global population aging and the widespread use of anticoagulant and antiplatelet medications.Although conventional burr-hole drainage is the most widely adopted approach,its recurrence rates remain considerable high,and surgical tolerance is poor in elderly patients.Therefore,we should underscore the urgent need to reassess clinical strategies for this disease.Middle meningeal artery embolization(MMAE)exerts a therapeutic effect by interrupting the blood supply to the hematoma capsule,thereby targeting the pathological source of disease progression.In particular,4 recent large-scale multicenter randomized controlled trials(EMBOLISE,MAGIC-MT,STEM,and EMPROTECT)have preliminary provided evidence-based validation of the safety and efficacy of MMAE.The clinical benefit of MMAE is particularly pronounced in symptomatic patients without emergency surgical indications,those on anticoagulant/antiplatelet therapy,patients with recurrent hematoma,and those at high surgical risk.Meanwhile,perioperative multimodality imaging assessment of the architecture of feeding arteries and the perfusion of hematoma capsule facilitates the prediction for therapeutic efficacy,early warning of recurrence,and formulation of individualized embolization strategies.Technically,hybrid surgical approaches and transradial artery access provide safer treatment options for high-risk patients,while the selection of embolic materials varies according to specific clinical scenarios.Based on the evolving evidence and clinical experience in MMAE,we propose a core conceptual advancement in the endovascular treatment of CSDH which is a shift from isolated middle meningeal artery embolization toward precise embolization of the hematoma capsule arterial supply under the guidance of imaging assessment of capsule blood supply,thereby achieving the goal of precise and effective individualized treatment.
陈志;李文䶮
陆军军医大学(第三军医大学)第一附属医院神经外科,重庆陆军军医大学(第三军医大学)第一附属医院神经外科,重庆
医药卫生
慢性硬膜下血肿脑膜中动脉栓塞血肿包膜血供患者分层个体化治疗
chronic subdural hematomamiddle meningeal artery embolizationblood supply for hematoma capsulepatient stratificationindividualized therapy
《陆军军医大学学报》 2026 (17)
2381-2389,9
创伤与化学中毒全国重点实验室开放基金(SKLO202505)陆军军医大学红医苗圃人才项目 Supported by the Open Fund of State Key Laboratory of Trauma and Chemical Poisoning(SKLO202505),and the Red Medical Nursery Talent Program of Army Medical University.
评论